# Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

> **NCT02513355** · PHASE4 · UNKNOWN · sponsor: **Nanjing NingQi Medicine Science and Technology Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Endostar
- **DRUG:** Changchun marina
- **DRUG:** cisplatin
- **DRUG:** Taxol
- **DRUG:** parapl

## Key facts

- **NCT ID:** NCT02513355
- **Lead sponsor:** Nanjing NingQi Medicine Science and Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-11
- **Final completion:** —
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2015-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513355, "Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02513355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*